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Michael J. Singh, MD,a and Karl A. Illig, MD,a Rochester, NY
Objective: To evaluate the cost-effectiveness of endovascular repair (EVAR) for small abdominal aortic aneurysms (AAA).
Methods: We developed a Markov model of a hypothetical 68-year-old cohort to determine the cost-effectiveness of early
EVAR for “small” AAAs (4.0 cm-5.4 cm) compared with elective repair (open or endovascular) at the traditional cut-off
of 5.5 cm. Repair options for 5.5-cm AAAs include both endovascular and open procedures. Probabilities were obtained
from the literature. Costs reflected direct costs in 2007 dollars. Outcomes were reported as quality-adjusted life-years
(QALYs).
Results: The model demonstrated that early EVAR for 4.0 cm-5.4 cm AAAs led to fewer QALYs at greater costs when
compared with observational management with elective repair at 5.5 cm. Sensitivity analyses suggested that early EVAR
of 4.6 cm-4.9 cm AAAs can be cost-effective if the long-term mortality rate after EVAR is<1.91% per year or if the quality
of life after EVAR is improved. Likewise, if the quality of life before repair is low, EVAR for AAAs >4.6 cm may be
cost-effective. With a>70% probability, observational management until AAA diameter is 5.5 cm will be the cost-effective
option.
Conclusions: This analysis demonstrated that early EVAR for AAAs <5.5 cm is not likely to be cost-effective compared
with elective repair at 5.5 cm. However, EVAR for small AAAs may become cost-effective when differences in quality of
life and mortality are considered. (J Vasc Surg 2010;51:27-32.)Based on a study of open surgical repair and observa-
tional management, abdominal aortic aneurysms (AAAs)
are considered for repair when they reach 5.5 cm in
diameter.1 Endovascular repair (EVAR) of AAAs 5.5
cm has demonstrated improved survival and lower rates
of reintervention compared with EVAR of larger AAAs.
These observations were also found when comparing
AAAs 5.0 cm to AAAs  6.0 cm.2 At our institution,
subjects with AAAs 5.0 cm may be considered for
EVAR. At least one ongoing randomized trial comparing
EVAR for small AAAs and observational management is
underway.3
The question of observational management or EVAR
for AAAs 5.5 cm can also be addressed using current
outcomes and Markov modeling. Thus, the goal of this
report is to explore the cost-effectiveness of EVAR for
AAAs 5.5 cm. Our model evaluates direct medical costs,
morbidity, and mortality following EVAR for AAAs 5.5
cm and weighs these factors against observational manage-
ment with elective repair at 5.5 cm.
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Target population. The hypothetical cohort was 68
years old with an initial AAA diameter of 4.0 cm.
Model description. The health states were observa-
tional management, post-EVAR, post-open surgical repair,
major stroke, dialysis, amputation, and death. Minor
stroke, myocardial infarction (MI), bowel ischemia, infec-
tion, and pneumonia were temporary health states. The
only transitions allowed from major stroke, dialysis, or
amputation were to continue in the current state or death
(Fig 1).
The cohort began in observational management, where
aneurysm diameter grew with time. Annual aneurysm
growth had a linear and a quadratic component.4 The base
case growth rate was about 2.7 mm per year. Once the
AAA size exceeded a prespecified size (range, 4.0 cm-5.5
cm), a proportion of the cohort underwent EVAR.
Those who were not suitable candidates for EVAR were
returned to an observational management state, in which
elective open surgical repair was performed once the
AAA diameter reached 5.5 cm. Those who required a
second AAA repair procedure could undergo either
EVAR or open surgical repair and were transitioned to
the appropriate health state.
Rupture risk for those in observational management
varied with aneurysm size. Rupture risks for AAAs repaired
by EVAR or open surgical repair were adapted from the
literature.5 Ruptured AAAs could be repaired by either
EVAR or open surgical repair.
Perspective, boundaries, time horizon. The payer
perspective was used and included only direct medical
costs. The time horizon was the lifetime of the cohort.
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events were possible each time endovascular or open surgi-
cal repair was needed (Table I).5 Long-term event proba-
bilities were based on a variety of sources from the litera-
ture. The probability of reintervention after EVAR was the
combined probability of repair for endoleak and repair for
graft migration based on third-generation endografts.6 An
increased mortality rate for those with end-stage renal
disease was incorporated into the model.7,8
Cost and utilization data.Costs represent direct med-
ical costs in 2007US dollars (Table I). Costs were obtained
from publically available sources or from Medicare charges
(changed to costs using cost-to-charge ratios).9 References
are listed in Table I. Where possible, nationally-based cost
estimates, rather than costs from a single institution, were
used to provide a broadly applicable analysis. Prices were
adjusted using the Consumer’s Price Index for medical
care. Future costs and utilities were discounted at 3%.10
Utility data. Utility data, or preferences for a health
state, were obtained from the literature (Table I). Quality-
adjusted life-years (QALYs) are the utility of a given health
state multiplied by the duration of the health state summed
across the life span of the cohort. Perfect health and death
represent health state preferences at 1.0 and 0, respectively.
Infection and pneumonia were assumed to affect quality of
life for 6 months.11
Analysis. EVAR for AAAs 4.0 cm to 5.5 cm was
considered the intervention branch. The comparator was
observational management of all AAAs until 5.5 cm, at
which to point the aneurysm was repaired by EVAR or
open surgical repair. The goal of the analysis was to deter-
mine the benefits of repair of AAA at diameters between 4.0
cm and 5.5 cm. Deterministic sensitivity analyses were
two-way sensitivity analyses with the parameter of interest
and AAA size varying from 4.0 cm to 5.5 cm. The willing-
ness to pay was $100,000/QALY, a threshold above which
interventions were deemed too expensive. Willingness to
pay is a tool assigning an economic value to 1 year of perfect
Fig 1. State transition diagram. Temporary states include minor
stroke, MI, bowel ischemia, infection, vessel rupture, and en-
doleak. Those entering a temporary state are returned to the
appropriate post-EVAR or post-open surgical repair. Permanent
health states include dialysis, major stroke, and amputation.
EVAR, Endovascular repair; MI, myocardial infarction.health. These deterministic sensitivity analyses changedindividual parameters, one at a time, over a range of AAA
sizes. In reality, costs, utilities, and probabilities vary simul-
taneously. A probabilistic sensitivity analysis was conducted
using 1,000 random samples of all parameters to assess
second-order uncertainty within the model (see Table I for
the list of variables and distributions).
RESULTS
Base case analysis. Early EVAR of 5.0-cm AAAs pro-
duced 0.05 fewer QALYs at an increased cost of $3000
(Table II). The same trend, less quality of life at a greater
cost, was found for early EVAR of AAAs as small as 4.0 cm.
Thus, EVAR of AAAs smaller than 5.5 cm is not cost-
effective.
Deterministic sensitivity analyses. We tested the pa-
rameters in the model over a range of values. All of the
sensitivity analyses were conducted as two-way analyses
with the variable of interest and AAA size cut-offs. The
willingness to pay was $100,000/QALY. In general, open
surgical repair was more cost-effective than EVAR. When
5% of the cohort were candidates for EVAR, early EVAR
was cost-effective starting at 4.6 cm. If the mortality rate
after EVAR was 1.91% per year (age-adjusted to 68
years), EVAR of AAAs between 4.9 cm and 5.5 cm became
cost-effective. When the rupture rate for 5-cm to 6-cm
AAAswas13.4%per year, EVAR forAAAdiameters starting
at 5.2 cmwas cost-effective. Increasing the linear or quadratic
component for AAA expansion suggested that cost-effective
EVAR repair of rapidly expanding AAAs began at 5.2 cm.
We also tested the assumptions about costs and utili-
ties. Worsening quality of life with an AAA favored repair at
smaller diameters (Fig 2A, at and below the line). When the
long-term utility after EVAR (beyond the first year) im-
proved to 0.89, repair of AAAs 4.6 cm or larger was
cost-effective (Fig 2B, at and above the line). Repair of
4.3-cm AAAs would be justified if EVAR returned the
subject to near-perfect health (0.99). None of the as-
sumptions about the cost parameters influenced the model.
Probabilistic sensitivity analysis. A probabilistic sen-
sitivity analysis was used to determine the probability that
either the choice to repair AAAs 5.5 cm or observe until
5.5 cm is beneficial at different economic values for 1
year of optimal health. The parameter estimates for costs,
quality of life, and probabilities of adverse events were
sampled simultaneously (Fig 3). Diameters of small
AAAs for EVAR ranged from 4.0 cm to 5.4 cm. With a
willingness to pay of $50,000/QALY, observation until
an AAA size of 5.5 cm has a 79% probability of being the
cost-effective choice. Observational management has a
72% probability of being cost-effective when the willingness-
to-pay is $100,000/QALY.
DISCUSSION
This cost-effective analysis shows that EVAR for AAAs
5.5 cm in diameter results in higher direct medical costs
for fewer QALYs gained. Also, with 72% probability,
observational management is the welfare-enhancing choice
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 1 Young et al 29Table I. Base case probabilities for transitions to health states or adverse events, costs (2007 dollars), and utilities
incorporated into the model
Base case Range Distribution References
Parameter
Aneurysm size, initial (cm) 4.0 3.5-5.5 Uniform
Linear expansion coefficient 0.26 0.24-0.28 Normal 4
Quadratic expansion coefficient 0.011 0.003-0.02 Normal 4
Age, initial (years) 68 60-75 Uniform
Threshold for repair (cm) 4.1-5.5 Triangular
Probabilities
Aneurysm does not grow 0.064 0-0.3 Beta 4
Infection, case fatality 0.24 0-0.75 Beta 20
MI, case fatality 0.024 0-0.1 Beta 21
MI, per year after repair 0.012 0-0.05 Beta 22
Repair EVAR 0.4 0-1 Triangular 23
Rupture, fatal, outside hospital 0.4 0.16-0.59 Triangular 24, 25
Rupture, % repaired by EVAR 0.43 0-1 Triangular 23
Rupture, fatal, EVAR 0.19 0-0.5 Beta 23
Rupture, fatal, open 0.38 0-0.5 Beta 26, 27
Rupture, 4-5 cm 0.01 0-0.095 Beta 13, 28
Rupture, 5-6 cm 0.063 0-0.24 Beta 13, 28
Rupture, 6-7 cm 0.097 0-0.36 Beta 13, 29
Rupture, 7-8 cm 0.28 0-0.75 Beta 13, 29
Rupture, 8 cm 0.33 0-0.9 Beta 13
Stroke, per year after repair 0.002 0-0.01 Beta 30
Stroke, % minor 0.264 0-0.5 Triangular 31
Stroke, major, case fatality 0.13 0-0.2 Beta 32-34
EVAR 30-day
Amputation 0.0004 0-0.01 Beta 5
Bowel ischemia 0.010 0-0.1 Beta 5
Dialysis 0.004 0-0.02 Beta 5
Infection 0.0001 0-0.01 Beta 5
MI 0.068 0-0.25 Beta 5
Mortality 0.012 0-0.1 Beta 5, 35, 36
Pneumonia 0.089 0-0.45 Beta 5
Stroke 0.026 0-0.2 Beta 5
Long-term, per year
Endoleak/reintervention 0.059 0-0.3 Beta 6
Repair for this is EVAR 0.62 0-1 Triangular
Infection 0.0056 0-0.03 Beta 20
Mortality, excess 0.029 0-0.06 Beta 12
Rupture 0.005 0-0.05 Beta 5
Open surgical repair 30-day
Amputation 0.0013 0-0.01 Beta 5
Bowel ischemia 0.021 0-0.1 Beta 5
Dialysis 0.005 0-0.02 Beta 5
Infection 0.0009 0-0.01 Beta 5
MI 0.09 0-0.25 Beta 5
Mortality 0.047 0-0.25 Beta 5, 35, 36
Pneumonia 0.16 0-0.45 Beta 5
Stroke 0.01 0-0.2 Beta 5
Long-term, per year
Infection 0.0019 0-0.03 Beta 20
Mortality, excess 0.0293 0-0.06 Beta 12
Rupture 0.0012 0-0.05 Beta 6
Costs (2007 $)
AAA endovascular repair 21,000 10,000-50,000 Triangular 37
AAA open repair 19,700 10,000-50,000 Triangular 37
Amputation, long-term 20,900 9,500-38,000 Triangular 38, 39
Dialysis, renal failure 89,500 37,750-155,000 Triangular 40, 41
EVAR, follow-up 1750 250-4000 Triangular
Infection, first 2 years 9700 4,150-16,600 Triangular 42
Infection, after 2 years 14,200 6,100-24,400 Triangular 42
Major stroke, hospitalization 15,000 6,000-26,000 Triangular 42-47
Major stroke, 1st year 58,800 40,000-80,000 Triangular 43, 48-50
nd 43, 48-50Major stroke, 2 year 30,600 15,000-45,000 Triangular
I, my
als.
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the current algorithm of observational management until
the aneurysm reached 5.5 cm in diameter.
Contrary to this report, two retrospective studies sug-
gest that EVAR of “small” AAAs is associated with better
outcomes.2,12 Our model is based on analysis of a larger
Medicare data set (22,000 records),5 a large registry
database (6700 records),6 and a randomized trial.13 Our
analysis also delineates circumstances in which EVAR
would be a suitable option for AAAs 5.5 cm. EVAR of
4.9-cm AAAs becomes cost-effective when the long-term
mortality rate after EVAR 1.91% per year (almost to the
level of the age-adjusted US population) while the surgical
mortality rate is held at 4.5% (age-adjusted to 68 years).
EVAR of 5.2-cm AAAs would be suitable for either rapidly
expanding AAAs (0.28 cm/year, base case  0.27 cm/
year) or when the rupture risk for 5-6 cm AAAs is 13.4%
per year. This 13.4% rupture risk may be roughly double
the actual risk but is within the upper limit of estimated risks
for AAAs of this size (3%-15%).14
Quality of life before and after repair also influenced
the cost-effectiveness of EVAR for small AAAs. Improve-
ments in quality of life with EVAR increase the number
of QALYs generated by the model and thus create a
potentially cost-effective intervention. A poorer quality
Table I. Continued
Base case
MI 15,600
MI, fatal 19,250
Minor stroke 15,000
Open repair, follow-up 180
Observational management 90
Utilities
Observation with AAA 0.75
EVAR, 1st year 0.7
EVAR, 2 years 0.71
Open 0.71
Amputation 0.65
MI 0.79
Minor stroke 0.73
Major stroke 0.21
Pulmonary 0.91
Renal 0.64
Bowel ischemia 0.64
Discount rate 3%
AAA, Abdominal aortic aneurysm; EVAR, endovascular aneurysm repair; M
Table II. Base case analysis
Cost (2007 $) Incremental cost
Repair at 5 cm 30,900
Repair at 5.5 cm 27,900 () 3,000
QALY, Quality-adjusted life-years.
Values were obtained using a Markov cohort of 1,000 hypothetical individuof life prior to repair (due to anxiety over the AAA, forexample), leads to greater quality of life gains after
repair. Higher utilities after EVAR,0.89, also generate
more QALYs. Restoring quality of life to 0.89 is im-
proving one’s health dramatically because the quality of
life with an AAA is estimated at 0.75.15-17 However, at
the population level, quality of life changes with EVAR
do not show drastic improvements.15-17
Our model is consistent with other cost-effectiveness
analyses that show favorable health benefits for open surgi-
cal repair compared with EVAR.18,19 Additionally, the
UK-Small Aneurysm Trial demonstrated that early open
surgical repair of AAAs 4.5 cm produced small quality of
life gains at a minimal cost.20 This is consistent with our
model in which EVAR for smaller AAAs does not produce
substantive health gains.
One limitation to this study is that the model does not
incorporate individually measured cost and utility values.
Nonetheless, this analysis includes point estimates from a
large Medicare population.5 This analysis does not include
indirect medical costs that may differ following open surgi-
cal repair or EVAR. Lost productivity and other expenses
are of value to society as a whole. Finally, we included
absolute aneurysm size based on different growth rates but
not the influences of other health conditions such as family
history or chronic obstructive pulmonary disease (COPD).
We addressed family history, other comorbidities and ana-
Range Distribution References
6,700-26,800 Triangular 42
8,250-33,000 Triangular 42
6,000-26,000 Triangular 42-47
0-400 Triangular
0-200 Triangular
0.5-1.0 Triangular 14-16
0.3-1.0 Triangular 14-16
0.3-1.0 Triangular 14-16
0.3-1.0 Triangular 14-16
0.4-0.9 Triangular 51-55
0.5-1.0 Triangular 56, 57
0.5-1.0 Triangular 58-60
0-0.5 Triangular 58-61
0.8-1.0 Triangular 62
0.5-0.75 Triangular 63-65
0.5-0.75 Triangular 63-65
0-8 9
ocardial infarction.
QALY Incremental QALY ICER ($/QALY)
7.11
7.16 () 0.05 Dominanttomic features with a broad category—suitable for EVAR
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of many 30-day adverse events, long-term rupture, and
options for reintervention when necessary.
CONCLUSIONS
This cost-effectiveness analysis supports the current
practice of observational management for AAAs5.5 cm
in diameter. Simultaneously sampling all of the parame-
ters supports this conclusion; there is at least a 72%
likelihood that observational management until an AAA
diameter of 5.5 cm is beneficial over a range of economic
Fig 2. Deterministic two-way sensitivity analyses show the rela-
tionship between health state preferences of living with an AAA (A)
or after EVAR repair (B) and the AAA diameter for EVAR repair.
EVAR of small AAAs would be cost-effective, with a willingness to
pay of $100,000/QALY, when perceived health with an AAA is
poor or when health is greatly improved after repair. AAA, Ab-
dominal aortic aneurysm; EVAR, endovascular repair; QALY,
quality-adjusted life-years.values QALY.AUTHOR CONTRIBUTIONS
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Dr Ruth Bush (Temple, Tex). I congratulate Dr. Young and
the coauthors on the presentation of cost-effectiveness of endovas-
cular aneurysm repair. I also very much appreciate receiving the
manuscript well ahead of this meeting. I have the following ques-
tions and a comment:
1. This model takes into account the cost of repair. However, as
we all know, with endovascular aneurysm repair, the cost of
lifelong surveillance and secondary intervention does add to the
overall cost. Is there a way to include this in the model? And do
you think it matters, Dr. Young?
2. Some suggest that women should undergo intervention at
smaller aneurysm diameters due to differences in vessel size, and
we will hear about that later on today. Is there any way to
incorporate gender into this model?
3. As we all hear, almost on a daily basis, and I believe President
Obama is meeting with the AMA next week, health care reform
is near the top or at the top of the current administration’s
agenda. How do you see your conclusions fitting in or influ-
encing that agenda?
And my last thing to say is a comment. I believe your data set
is robust, your statistical analysis is exact and on target, and I would
encourage you, after reviewing the manuscript, that the purpose,results. I found those very good. Again, I appreciate the opportu-
nity to review this paper.
Dr Young. Gender is included inherently in the model based
on the probabilities of rupture and growth.
In terms of surveillance, costs for this after endovascular and
after open repair are assumed to be equal and thus wouldn’t
contribute to the incremental cost-effectiveness ratio. If one
requires more surveillance than the other, it is possible it could
change the incremental cost-effectiveness ratio, likely making
EVAR more expensive. This scenario would still favor waiting
because open repair is more cost-effective. None of the cost
assumptions in my model affected the results, but it is possible.
With a public health hat, we certainly need more information
from surgeons as to what the best size to intervene is, what are the
risks, and what are the benefits. This model and the information we
have collected can certainly be refined as more data become
available to help address these questions.
Dr Benjamin Starnes (Seattle, Wash). You’ve looked at the
cost-effectiveness using a Markov model of analysis and quality-
adjusted life-years based on size of the aneurysm. What are your
thoughts – and this is just asking you what your personal opinion
is – on a comparison of cost-effectiveness of screening for abdom-
inal aortic aneurysms versus the cost-effectiveness of treating a
ruptured aneurysm? Can you comment on that?
Dr Young.No. I’m not familiar with the cost-effectiveness for
screening of abdominal aortic aneurysms.
